Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Advanced Breast Cancer with PIK3CA/AKT Mutations or PTEN Loss
NCT01277757Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in breast cancer, sponsored by National Cancer Institute. Started Mar 2011; status: completed.
02
Drugs
MK-2206
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01277757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01277757.